Pharmahungary Group and Remembrane developed and validated a medium throughput in vitro screening platform for testing potential cardiocytoprotective drug candidates against ischemia/reperfusion injury in the presence of hypercholesterolemia/metabolic disease comorbidities.
The screening platform has been recently described in Frontiers in Physiology (Makkos et al., Front. Physiol. 2020; 10:1564.
The Press Release is available here: Pharmahungary-Remembrane_in-vitro-comorbidity-testing platform_press release
The Publication is available here: Makkos et al., 2020
Remembrane looks forward to the next collaboration step with our long-lasting Hungarian partner.
Happy Culturing!!!
Remembrane’s Team
